Athersys (ATHX) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Athersys Reports First Quarter 2015 Results
May 11, 2015 4:05 PM EDTCLEVELAND, May 11, 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) today announced its financial results for the three months ended March 31, 2015.
Highlights of the first quarter of 2015 and recent events include:
Entered into an exclusive license agreement with Chugai Pharmaceutical Co., Ltd. (Chugai) to develop and commercialize our MultiStem® cell therapy for the treatment of ischemic stroke in Japan, which included an up-front payment of $10 million and an additional $195 million of potential future payments and royalties;Announced interim results from the Phase 2 clinical study of MultiStem to... More